131 related articles for article (PubMed ID: 38175816)
61. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.
Gargiulo S; Torrini M; Ollila S; Nasti S; Pastorino L; Cusano R; Bonelli L; Battistuzzi L; Mastracci L; Bruno W; Savarino V; Sciallero S; Borgonovo G; Nyström M; Bianchi-Scarrà G; Mareni C; Ghiorzo P
Fam Cancer; 2009; 8(4):547-53. PubMed ID: 19728162
[TBL] [Abstract][Full Text] [Related]
62. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
63. Clinicopathological and molecular characterization of Brazilian families at risk for Lynch syndrome.
de Paula AE; Galvão HCR; Bonatelli M; Sabato C; Fernandes GC; Berardinelli GN; Andrade CEM; Neto MC; Romagnolo LGC; Campacci N; Scapulatempo-Neto C; Reis RM; Palmero EI
Cancer Genet; 2021 Jun; 254-255():82-91. PubMed ID: 33647816
[TBL] [Abstract][Full Text] [Related]
64. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
[TBL] [Abstract][Full Text] [Related]
65. Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).
Leenders EKSM; Westdorp H; Brüggemann RJ; Loeffen J; Kratz C; Burn J; Hoogerbrugge N; Jongmans MCJ
Eur J Hum Genet; 2018 Oct; 26(10):1417-1423. PubMed ID: 29904176
[TBL] [Abstract][Full Text] [Related]
66. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome.
Mas-Moya J; Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Hum Pathol; 2015 Nov; 46(11):1616-25. PubMed ID: 26319271
[TBL] [Abstract][Full Text] [Related]
67. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
[TBL] [Abstract][Full Text] [Related]
68. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
[TBL] [Abstract][Full Text] [Related]
69. Association of a novel frameshift variant and a known deleterious variant in MMR genes with Lynch syndrome in Chinese families.
Li J; Ni H; Wang X; Cheng W; Li L; Cheng Y; Liu C; Li Y; Deng A
World J Surg Oncol; 2024 Jan; 22(1):36. PubMed ID: 38280988
[TBL] [Abstract][Full Text] [Related]
70. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
[TBL] [Abstract][Full Text] [Related]
71. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
[TBL] [Abstract][Full Text] [Related]
72. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.
Maletzki C; Huehns M; Bauer I; Ripperger T; Mork MM; Vilar E; Klöcking S; Zettl H; Prall F; Linnebacher M
Mol Carcinog; 2017 Jul; 56(7):1753-1764. PubMed ID: 28218421
[TBL] [Abstract][Full Text] [Related]
73. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
74. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
[TBL] [Abstract][Full Text] [Related]
75. Mismatch repair deficiency and MUTYH variants in small intestine-neuroendocrine tumors.
Helderman NC; Elsayed FA; van Wezel T; Terlouw D; Langers AMJ; van Egmond D; Kilinç G; Hristova H; Farina Sarasqueta A; Morreau H; Nielsen M; Suerink M;
Hum Pathol; 2022 Jul; 125():11-17. PubMed ID: 35417733
[TBL] [Abstract][Full Text] [Related]
76. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.
Wong S; Hui P; Buza N
Mod Pathol; 2020 Jun; 33(6):1172-1181. PubMed ID: 31932681
[TBL] [Abstract][Full Text] [Related]
77. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
[TBL] [Abstract][Full Text] [Related]
78. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
Kravochuck SE; Church JM
ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
[TBL] [Abstract][Full Text] [Related]
79. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
[TBL] [Abstract][Full Text] [Related]
80. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
